ARID1A and neoplasm: If this is the case, unless some other alteration in the tumour cell can compensate for the restoration of ARID1A function, then it is unlikely that reversion of an ARID1A mutation is likely to be tolerated by the tumour cell, making it unlikely that reversion of this gene emerges as a cause of ATRi resistance.